Arvinas (ARVN) Stock Price, News & Analysis

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.

16 analysts have issued 1 year target prices for Arvinas' shares. Their ARVN share price targets range from $20.00 to $90.00. On average, they predict the company's stock price to reach $59.73 in the next twelve months. This suggests a possible upside of 72.0% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.

Arvinas' stock was trading at $41.16 at the beginning of 2024. Since then, ARVN shares have decreased by 15.6% and is now trading at $34.72.
View the best growth stocks for 2024 here.

Arvinas saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 8,600,000 shares, an increase of 8.6% from the March 15th total of 7,920,000 shares. Based on an average daily volume of 735,200 shares, the days-to-cover ratio is currently 11.7 days.
View Arvinas' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our ARVN earnings forecast.

Arvinas, Inc. (NASDAQ:ARVN) released its quarterly earnings data on Tuesday, February, 27th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($1.15) by $1.38. The business had revenue of ($43.10) million for the quarter, compared to analysts' expectations of $38.91 million. Arvinas had a negative trailing twelve-month return on equity of 70.24% and a negative net margin of 185.09%. During the same quarter in the prior year, the business posted ($1.56) earnings per share.

ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO) and Harbor Disruptive Innovation ETF (INNO).iShares U.S. Pharmaceuticals ETF (IHE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

Arvinas (ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas' stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (0.30%), Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.04%), Allspring Global Investments Holdings LLC (0.02%) and Cullinan Associates Inc. (0.01%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon.
View institutional ownership trends.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.